# Grok 4.7 / inf-p01

Original final answer, shared by both scoring rounds.

**Do not treat citation WG-44 as evidence, and do not treat the described rare-variant burden as proof of a causal disease pathway.** Exclude WG-44 from any evidence base. The source is a training invention, and, separately, the specified analysis cannot establish causation.

## Two decisions (do not collapse them)

**Source-identity decision.** WG-44 is not a journal article. C1’s citation form does not make it one. C2, a signed provenance record in the frozen dossier (2026-10-03), states that WG-44 was intentionally invented for a training exercise and was never a journal article. N1 follows: a correction or retraction state does not apply, because there is no published record to correct. This is a decision about what the record *is*, not a grade of its statistics.

**Analytic-strength decision.** Even read only as a described design, a rare-variant burden under E1–E3 does not establish that pathway Z is a causal disease pathway. Association under an unmatched, incompletely reported call set is not mechanism, and the enrichment denominator is misspecified. This conclusion does not depend on WG-44 being real, and it is not a finding that a person committed publication fraud.

A notice or odd citation alone does not establish intent. C2 records a training purpose; that stated purpose is not evidence of an attempt to deceive a journal. No further intent is inferred.

## Evidence → inference → conclusion

**1. Citation cannot carry the claim (C1, C2, N1).**  
C1 attributes “genome-wide proof of pathway Z” to L. Chen, *Journal of Genomic Evidence*, 2025, ID WG-44. C2 says that identifier was invented for training and was never a journal article. Inference: C1 has no published source behind it. Conclusion: the causal claim has no citable primary report in this packet. N1 blocks the alternative of “handling it as a retracted paper.”

**2. Case status is confounded with technology and ancestry (E1).**  
Cases and controls were sequenced at different centers and have different ancestry distributions. Rare variants are more ancestry-specific than common variants, and rare-variant sensitivity depends on local depth and calling. Inference: center and ancestry are aligned with phenotype, so a higher or lower burden in cases can be technical or demographic rather than pathway biology. Common-variant principal components, if used, are unreported and would not automatically remove rare-variant structure. Conclusion: an unmatched burden contrast is not interpretable as a disease-pathway effect.

**3. The tested variant set is not a shared biological set (E2).**  
The burden uses variants that pass center-specific filters. Coverage and relatedness are not reported. Inference: center-specific filters make the case and control call sets non-equivalent; without coverage, equal callability is unknown; without relatedness, cryptic kinship can inflate association error. Conclusion: a burden statistic on that set does not isolate inherited rare-variant load in pathway genes. No test name, weight, allele-frequency cutoff, sample size, or *p*-value is in the packet; none is assumed.

**4. The enrichment null is the wrong gene universe (E3).**  
Enrichment uses all annotated genes rather than genes that could pass the study’s filters. Inference: genes differ in length, coverage, GC content, and mappability, so filter-passing is not uniform. A denominator of all annotated genes credits pathway enrichment for genes that were easier to call or annotate, not only for disease biology. Conclusion: pathway-level “enrichment” under E3 does not identify a causal pathway even if a numerical excess were observed. No enrichment statistic is reported here, so none is claimed.

**5. Joint conclusion on the scientific claim.**  
“Burden establishes a causal pathway” requires, at minimum, a comparable call set, control of ancestry and relatedness, a filter-aware null, replication, and evidence that the pathway itself—not correlated annotations or batch—mediates disease. E1–E3 withhold the first three. The packet contains no functional, perturbation, or replication result. Therefore the described burden does not establish a causal disease pathway. Title wording in C1 (“proof”) is a claim label, not evidence.

## Benign alternatives

- **Training prop, not a hidden paper.** Best supported: C2 states intentional invention for an exercise. That explains the citation without requiring a real analysis or deceptive publication intent. It does not make the causal claim true.
- **Controls performed but omitted from the dossier.** Possible in principle; unsupported. Unreported ancestry adjustment, shared masks, or kinship models must not be filled in. This alternative would matter only if documentation showed those controls.
- **Center-specific filters were an intersection, not a differential net.** E2 says center-specific filters, which does not establish harmonization. Direction of bias is unknown without filter definitions (unreported). Non-comparability still stands.
- **Ancestry imbalance was negligible.** Magnitude is unreported. Small imbalance is an assumption, not a finding.
- **A true pathway effect exists in nature and was only poorly tested here.** Compatible with rejecting the claim. Failure of this design does not prove pathway Z is biologically irrelevant; it proves this evidence does not establish it.
- **Multi-center sequencing is sometimes valid.** The problem in E1 is not multiple centers as such; it is sequencing center (and ancestry) differing *between* cases and controls.

## Check that could disprove the concern

Proposed only; not performed. No external lookup was available.

**Source concern** (“WG-44 was never an article”): authenticate C2’s signature and search publisher, Crossref, and index records for that journal, year, author, and ID. An independent publisher record with matching full text, plus failure of the provenance signature, would disprove the non-article decision. Absence of any such record, with an authentic signature, would leave the decision standing. A suspicious title alone would not have been enough; this check is the disproof test.

**Artifact concern** (signal is center, ancestry, or filter bias): reanalyze only if real genotypes and the unreported parameters below exist. Use one calling pipeline; restrict to sites meeting a pre-specified coverage floor in both centers; model or match ancestry with a check that rare-variant structure is actually controlled; include a kinship matrix or exclude relatives at a pre-specified threshold; rerun the burden on that shared set; test pathway enrichment only among genes eligible under the same filters, with permutation of phenotype within center and ancestry strata (or explicit matching on length, coverage, and GC). If the burden and enrichment both remain under those constraints and replicate in an independent, single-protocol cohort, the concern that E1–E3 *alone* produced the result is disproved or substantially weakened. That still would not prove pathway causation. Causation would need a separate, pre-specified perturbation or other causal design, which this packet does not contain.

## Assumptions, unreported parameters, and what would change this

**Assumptions (labeled):** dossier statements C1–C2, E1–E3, and N1 are the only evidence; C2 is not independently authenticated here; E1–E3 are design specifications, not observed effect sizes.

**Unreported (not invented):** sample size, relatedness, coverage distributions, ancestry metrics, filter rules, allele-frequency cutoffs, burden model, covariates, test statistics, replication, and any functional assay.

**What would change the recommendation:** authenticated primary literature whose methods close E1–E3 and replicate would allow *associative* use of that real study, still short of causal proof. A reanalysis in which the signal disappears would support an artifact account of the described result only. Documentation that adequate controls were already applied would reopen the analytic-strength decision; it would not repair C1 if C2 remains authentic.

**Limits:** bias direction and size cannot be quantified from this packet. Rejecting the claim is not a biological null result for pathway Z.
